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Reply
We appreciate the opportunity to reply to questions raised by Dr.
Nakazawa and colleagues. Please note that the coronary arteries
distal to the stented segment but not the stented lesion were
examined for the endothelial vasomotor function in our study (1).
As described in our study (1), myocardial ischemia-reperfusion
induces endothelial injury in the coronary trees for their entirety
distal to the occluded segment in the infarct-related coronary
artery. Thus, the healing process of the coronary arteries distal to
the stented segment but not the stented lesion affected our data.
Our previous reports (2–5) agreed that the atherosclerotic burden
strongly affects coronary endothelial vasomotor functions. How-
ever, our study (1) showed that the frequencies of the atheroscle-
rotic risk factors were comparable between the drug-eluting stent
(DES) and bare-metal stent (BMS) groups. In addition, the 2
groups had no difference in cardiac medications, lesion, and
procedural variables of percutaneous coronary intervention except
for stent selection, and acute myocardial infarction (AMI)–related
variables that potentially influence the coronary endothelial vaso-
motor function, as described in our study (1). Thus, the implanted
stents were only the discriminate factor for the difference in the
coronary endothelial vasomotor responses to acetylcholine between
the patients treated with BMS and DES.
A number of previous reports (6,7) demonstrated that the
vascular endothelial growth factor (VEGF) expression is increased
in cardiomyocytes as well as vascular endothelial cells in ischemic
or injured hearts and that sirolimus is capable of inhibiting VEGF
production and the VEGF-mediated cellular signaling pathway in
various types of cells. Our study (1) also showed that VEGF levels
in the anterior interventricular vein (AIV), reflecting VEGF levels
released from the ischemic myocardium, were increased in AMI
patients treated with BMS compared with control subjects. As we
described in our study (1), sirolimus levels in AIV in our study
were 10- to 500-fold lower than the levels to exert its biological
effects in vitro experiments (8,9). Considering the fact that
sirolimus is eluted into coronary circulation over a period of 4
weeks, these exposure times were much longer as compared with
the in vitro experiments. Moreover, the chronic exposure to the
circulating sirolimus might cause a local accumulation of consid-
erable amounts of this drug in the myocardium and the entire
vascular bed distal to sirolimus-eluting stent (SES) in the infarct-
related coronary artery. Thus, there is a possibility that SES could
induce a decrease in VEGF release from myocardium and endo-
thelium of large and resistance vessels, which may play a possible
role in the mechanisms for endothelial vasomotor dysfunction in
the infarct-related coronary arteries treated with SES.
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Early Detection of
Rheumatic Heart Disease
and Prevention of Heart
Failure in Sub-Saharan Africa
In a recent issue of the Journal, Damasceno et al. (1) highlighted
the need for action to reduce the prevalence of heart failure in
sub-Saharan Africa, where this pathology is an important cause of
mortality as well as a serious economic burden. Rheumatic heart
disease is the most frequent cause of heart failure in this region of
the world and is responsible for at least one-third of cases. In this
context, the authors are prudent to insist on the need for a strategy
of prevention with regards to risk factors for heart failure. Never-
theless, we would like to underline important new findings that
should be considered when attempting to reduce the incidence of
this life-threatening pathology.
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